| http://www.w3.org/ns/prov#value | - EST to discuss the announcement made Saturday, December 7, 2013 on the worldwide license and option agreements it entered into with Cedars-Sinai Medical Center (Cedars-Sinai) for the development of new drugs to target non-bacterial intestinal microorganism life forms known as archaea that are associated with chronic diseases such as irritable bowel syndrome (IBS), obesity and type 2 diabetes.
|
